Download - EULAR Textbook on Rheumatic Diseases 23 - module 20.pdf · EULAR Textbook on Rheumatic Diseases References chapter 23 1. Preliminary criteria for the classification of systemic sclerosis

EULAR Textbook on Rheumatic Diseases

References chapter 23

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma).

Subcommittee for scleroderma criteria of the American Rheumatism Association

Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23(5):581-90.

2. Poormoghim H, Lucas M, Fertig N, Medsger TA, Jr. Systemic sclerosis sine

scleroderma: demographic, clinical, and serologic features and survival in forty-eight

patients. Arthritis Rheum 2000;43(2):444-51.

3. Mayes MD, Lacey JV, Jr., Beebe-Dimmer J, Gillespie BW, Cooper B, Laing

TJ, et al. Prevalence, incidence, survival, and dis ease characteristics of systemic

sclerosis in a large US population. Arthritis Rheum 2003;48(8):2246-55.

4. Czirjak L, Kiss CG, Lovei C, Suto G, Varju C, Fuzesi Z, et al. Survey of

Raynaud's phenomenon and systemic sclerosis based on a representative study of

10,000 south-Transdanubian Hungarian inhabitants. Clin Exp Rheumatol

2005;23(6):801-8.

5. Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID. A study of the prevalence

of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004;43(5):596-602.

6. Kettaneh A, Al Moufti O, Tiev KP, Chayet C, Toledano C, Fabre B, et al.

Occupational exposure to solvents and gender-related risk of systemic sclerosis: a

metaanalysis of case-control studies. J Rheumatol 2007;34(1):97-103.

7. Bovenzi M, Barbone F, Pisa FE, Betta A, Romeo L, Tonello A, et al. A case-

control study of occupational exposures and systemic sclerosis. Int Arch Occup Environ

Health 2004;77(1):10-6.

8. Mayes MD. Epidemiologic studies of environmental agents and systemic

autoimmune diseases. Environ Health Perspect 1999;107 Suppl 5:743-8.

9. Diot E, Lesire V, Guilmot JL, Metzger MD, Pilore R, Rogier S, et al. Systemic

sclerosis and occupational risk factors: a case-control study. Occup Environ Med

2002;59(8):545-9.

10. Garabrant DH, Lacey JV, Jr., Laing TJ, Gillespie BW, Mayes MD, Cooper BC, et

al. Scleroderma and solvent exposure among women. Am J Epidemiol 2003;157(6):493-

500.

EULAR Textbook on Rheumatic Diseases 11. Jimenez SA, Artlett CM. Microchimerism and systemic sclerosis. Curr Opin

Rheumatol 2005;17(1):86-90.

12. Hamamdzic D, Kasman LM, LeRoy EC. The role of infectious agents in the

pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2002;14(6):694-8.

13. Herrick AL, Matucci Cerinic M. The emerging problem of oxidative stress and the

role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001;19(1):4-8.

14. Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr

Rheumatol Rep 2002;4(2):99-107.

15. Allanore Y, Dieude P, Boileau C. Updating the genetics of systemic sclerosis.

Curr Opin Rheumatol.

16. Jungel A, Ospelt C, Gay S. What can we learn from epigenetics in the year

2009? Curr Opin Rheumatol;22(3):284-92.

17. Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis.

Autoimmun Rev 2003;2(4):181-91.

18. Neidhart M, Kuchen S, Distler O, Bruhlmann P, Michel BA, Gay RE, et al.

Increased serum levels of antibodies against human cytomegalovirus and prevalence of

autoantibodies in systemic sclerosis. Arthritis Rheum 1999;42(2):389-92.

19. Jimenez SA, Diaz A, Khalili K. Retroviruses and the pathogenesis of systemic

sclerosis. Int Rev Immunol 1995;12(2-4):159-75.

20. Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin

lesions from women with systemic sclerosis. N Engl J Med 1998;338(17):1186-91.

21. Artlett CM. Microchimerism and scleroderma: an update. Curr Rheumatol Rep

2003;5(2):154-9.

22. Nelson JL. Microchimerism and HLA relationships of pregnancy: implications for

autoimmune diseases. Curr Rheumatol Rep 2001;3(3):222-9.

23. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am

1996;22(4):675-94.

24. Renaudineau Y, Revelen R, Levy Y, Salojin K, Gilburg B, Shoenfeld Y, et al.

Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol

1999;6(2):156-60.

25. Kahaleh B. Lymphocyte interactions with the vascular endothelium in systemic

sclerosis. Clin Dermatol 1994;12(3):361-7.

EULAR Textbook on Rheumatic Diseases 26. Kahaleh MB. Vascular involvement in systemic sclerosis (SSc). Clin Exp

Rheumatol 2004;22(3 Suppl 33):S19-23.

27. Gruschwitz MS, Hornstein OP, von Den Driesch P. Correlation of soluble

adhesion molecules in the peripheral blood of scleroderma patients with their in situ

expression and with disease activity. Arthritis Rheum 1995;38(2):184-9.

28. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules

(sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in

patients with systemic sclerosis: relationship to organ systemic involvement. Clin

Rheumatol 2005;24(2):111-6.

29. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy

assessment of microvascular damage in systemic sclerosis. J Rheumatol

2000;27(1):155-60.

30. Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A. Levels of

circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol

2007;25(1):60-6.

31. Avouac J, Juin F, Wipff J, Couraud PO, Chiocchia G, Kahan A, et al. Circulating

endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann

Rheum Dis 2008;67(10):1455-60.

32. Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C, et al. Bone

marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum

2006;54(8):2605-15.

33. Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, et al. Impairment

of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells:

new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum

2007;56(6):1994-2004.

34. Butler AR, Flitney FW, Williams DL. NO, nitrosonium ions, nitroxide ions,

nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol Sci

1995;16(1):18-22.

35. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI.

Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and

systemic sclerosis. J Rheumatol 1994;21(8):1477-83.

36. Avouac J, Borderie D, Ekindjian OG, Kahan A, Allanore Y. High DNA oxidative

damage in systemic sclerosis. J Rheumatol;37(12):2540-7.

EULAR Textbook on Rheumatic Diseases 37. Ogawa F, Shimizu K, Hara T, Muroi E, Hasegawa M, Takehara K, et al. Serum

levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients

with systemic sclerosis: association with fibrosis and vascular damage. Clin Exp

Rheumatol 2008;26(4):659-62.

38. Ogawa F, Shimizu K, Hara T, Muroi E, Komura K, Takenaka M, et al.

Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide

reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular

damage. Arch Dermatol Res;302(1):27-35.

39. Farina GA, York MR, Di Marzio M, Collins CA, Meller S, Homey B, et al. Poly(I:C)

drives type I IFN- and TGFbeta-mediated inflammation and dermal fibrosis simulating

altered gene expression in systemic sclerosis. J Invest Dermatol;130(11):2583-93.

40. Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically

involved skin from patients with systemic sclerosis of recent onset predominantly consist

of monocytes/macrophages. Pathobiology 1995;63(1):48-56.

41. Chizzolini C. T lymphocyte and fibroblast interactions: the case of skin

involvement in systemic sclerosis and other examples. Springer Semin Immunopathol

1999;21(4):431-50.

42. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD. Oligoclonal T cell

expansion in the skin of patients with systemic sclerosis. J Immunol 2002;168(7):3649-

59.

43. Radstake TR, van Bon L, Broen J, Wenink M, Santegoets K, Deng Y, et al.

Increased frequency and compromised function of T regulatory cells in systemic

sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS ONE

2009;4(6):e5981.

44. Klein S, Kretz CC, Ruland V, Stumpf C, Haust M, Hartschuh W, et al. Reduction

of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic

scleroderma. Ann Rheum Dis.

45. Avouac J, Furnrohr BG, Tomcik M, Palumbo K, Zerr P, Horn A, et al.

Inactivation of the transcription factor STAT-4 pre vents inflammation-driven

fibrosis in animal models of systemic sclerosis. Ar thritis Rheum;63(3):800-9.

46. Fenoglio D, Battaglia F, Parodi A, Stringara S, Negrini S, Panico N, et al.

Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with

systemic sclerosis. Clin Immunol.

EULAR Textbook on Rheumatic Diseases 47. Fujimoto M, Sato S. B lymphocytes and systemic sclerosis. Curr Opin Rheumatol

2005;17(6):746-51.

48. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in

systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007;56(9):3167-

8.

49. Fujimoto M, Sato S. B cell signaling and autoimmune diseases: CD19/CD22 loop

as a B cell signaling device to regulate the balance of autoimmunity. J Dermatol Sci

2007;46(1):1-9.

50. Odaka M, Hasegawa M, Hamaguchi Y, Ishiura N, Kumada S, Matsushita T, et al.

Autoantibody-mediated regulation of B cell responses by functional anti-CD22

autoantibodies in patients with systemic sclerosis. Clin Exp Immunol;159(2):176-84.

51. White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am

1996;22(4):695-708.

52. Postlethwaite AE. Role of T cells and cytokines in effecting fibrosis. Int Rev

Immunol 1995;12(2-4):247-58.

53. Varga J, Jimenez SA. Cutaneous sclerosis localized to one limb after

immobilization in a patient with CREST syndrome. J Rheumatol 1987;14(3):637-8.

54. Leask A, Holmes A, Abraham DJ. Connective tissue growth factor: a new and

important player in the pathogenesis of fibrosis. Curr Rheumatol Rep 2002;4(2):136-42.

55. Ihn H. The role of TGF-beta signaling in the pathogenesis of fibrosis in

scleroderma. Arch Immunol Ther Exp (Warsz) 2002;50(5):325-31.

56. Svegliati S, Cancello R, Sambo P, Luchetti M, Paroncini P, Orlandini G, et al.

Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein

levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in

systemic sclerosis fibroblasts. J Biol Chem 2005;280(43):36474-82.

57. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Sp adoni T, Mancini M, et al.

Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J

Med 2006;354(25):2667-76.

58. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr., et al.

Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol

1988;15(2):202-5.

59. Cutolo M, Grassi W, Matucci Cerinic M. Raynaud's phenomenon and the role of

capillaroscopy. Arthritis Rheum 2003;48(11):3023-30.

EULAR Textbook on Rheumatic Diseases 60. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamo wicz M, Boire G, et al.

Autoantibodies and microvascular damage are indepen dent predictive factors for

the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year

prospective study of 586 patients, with validation of proposed criteria for early

systemic sclerosis. Arthritis Rheum 2008;58(12):390 2-12.

61. Fiori G, Amanzi L, Moggi Pignone A, Braschi F, Matucci-Cerinic M. [The

treatment of skin ulcers in patients with systemic sclerosis]. Reumatismo

2004;56(4):225-34.

62. Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis:

outcomes and considerations. J Rheumatol 2005;32(4):642-8.

63. Nihtyanova SI, Brough GM, Black CM, Denton CP. Clinical burden of digital

vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis

2008;67(1):120-3.

64. Amanzi L, Braschi F, Fiori G, Galluccio F, Miniati I, Guiducci S, et al. Digital

ulcers in scleroderma: staging, characteristics and sub-setting through observation of

1614 digital lesions. Rheumatology (Oxford);49(7):1374-82.

65. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum

1994;37(9):1265-82.

66. Cohen S, Fisher R, Lipshutz W, Turner R, Myers A, Schumacher R. The

pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin

Invest 1972;51(10):2663-8.

67. Zamost BJ, Hirschberg J, Ippoliti AF, Furst DE, Clements PJ, Weinstein WM.

Esophagitis in scleroderma. Prevalence and risk factors. Gastroenterology

1987;92(2):421-8.

68. Klein HA, Wald A, Graham TO, Campbell WL, Steen VD. Comparative studies of

esophageal function in systemic sclerosis. Gastroenterology 1992;102(5):1551-6.

69. Wipff J, Allanore Y, Soussi F, Terris B, Abitbol V, Raymond J, et al. Prevalence

of Barrett's esophagus in systemic sclerosis. Arthritis Rheum 2005;52(9):2882-8.

70. Wipff J, Coriat R, Masciocchi M, Caramaschi P, Derk CT, Hachulla E, et al.

Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR

Scleroderma Trials and Research prospective follow-up study. Rheumatology (Oxford).

EULAR Textbook on Rheumatic Diseases 71. Leite LP, Johnston BT, Barrett J, Castell JA, Castell DO. Ineffective esophageal

motility (IEM): the primary finding in patients with nonspecific esophageal motility

disorder. Dig Dis Sci 1997;42(9):1859-65.

72. Wegener M, Adamek RJ, Wedmann B, Jergas M, Altmeyer P. Gastrointestinal

transit through esophagus, stomach, small and large intestine in patients with

progressive systemic sclerosis. Dig Dis Sci 1994;39(10):2209-15.

73. Marie I, Ducrotte P, Antonietti M, Herve S, Levesque H. Watermelon stomach in

systemic sclerosis: its incidence and management. Aliment Pharmacol Ther

2008;28(4):412-21.

74. Ingraham KM, O'Brien MS, Shenin M, Derk CT, Steen VD. Gastric antral

vascular ectasia in systemic sclerosis: demographics and disease predictors. J

Rheumatol;37(3):603-7.

75. Shibukawa G, Irisawa A, Sakamoto N, Takagi T, Wakatsuki T, Imamura H, et al.

Gastric antral vascular ectasia (GAVE) associated with systemic sclerosis: relapse after

endoscopic treatment by argon plasma coagulation. Intern Med 2007;46(6):279-83.

76. Greydanus MP, Camilleri M. Abnormal postcibal antral and small bowel motility

due to neuropathy or myopathy in systemic sclerosis. Gastroenterology 1989;96(1):110-

5.

77. Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al.

Reliability and validity of the University of California, Los Angeles Scleroderma Clinical

Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009;61(9):1257-63.

78. Steen VD, Conte C, Owens GR, Medsger TA, Jr. Severe restrictive lung disease

in systemic sclerosis. Arthritis Rheum 1994;37(9):1283-9.

79. Kim DS, Yoo B, Lee JS, Kim EK, Lim CM, Lee SD, et al. The major

histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial

pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002;19(2):121-7.

80. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P,

et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis

and their relationship to outcome. Am J Respir Crit Care Med 2002;165(12):1581-6.

81. Travis WD, Hunninghake G, King TE, Jr., Lynch DA, Colby TV, Galvin JR, et al.

Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society

project. Am J Respir Crit Care Med 2008;177(12):1338-47.

EULAR Textbook on Rheumatic Diseases 82. Guttadauria M, Ellman H, Emmanuel G, Kaplan D, Diamond H. Pulmonary

function in scleroderma. Arthritis Rheum 1977;20(5):1071-9.

83. Peters-Golden M, Wise RA, Hochberg MC, Stevens MB, Wigley FM. Carbon

monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med

1984;77(6):1027-34.

84. Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM, et al.

Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of

disease on computed tomography. Arthritis Rheum 1997;40(7):1229-36.

85. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum

Dis 2003;62(2):97-9.

86. Steen VD, Medsger TA, Jr. Severe organ involvement in systemic sclerosis with

diffuse scleroderma. Arthritis Rheum 2000;43(11):2437-44.

87. Remy-Jardin M, Remy J, Wallaert B, Bataille D, Hatron PY. Pulmonary

involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary

function tests, and bronchoalveolar lavage. Radiology 1993;188(2):499-506.

88. Ooi GC, Mok MY, Tsang KW, Wong Y, Khong PL, Fung PC, et al. Interstitial lung

disease in systemic sclerosis. Acta Radiol 2003;44(3):258-64.

89. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, et al.

Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial

lung disease. Am J Respir Crit Care Med 2008;177(1):91-8.

90. Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, et al.

Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for

the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther

2009;11(4):R111.

91. Pignone A, Matucci-Cerinic M, Lombardi A, Fedi R, Fargnoli R, De Dominicis R,

et al. High resolution computed tomography in systemic sclerosis. Real diagnostic

utilities in the assessment of pulmonary involvement and comparison with other

modalities of lung investigation. Clin Rheumatol 1992;11(4):465-72.

92. O'Brodovich H, Coates G. Pulmonary clearance of 99mTc-DTPA: a noninvasive

assessment of epithelial integrity. Lung 1987;165(1):1-16.

93. Pantin CF, Valind SO, Sweatman M, Lawrence R, Rhodes CG, Brudin L, et al.

Measures of the inflammatory response in cryptogenic fibrosing alveolitis. Am Rev

Respir Dis 1988;138(5):1234-41.

EULAR Textbook on Rheumatic Diseases 94. Susskind H. Technetium-99m-DTPA aerosol to measure alveolar-capillary

membrane permeability. J Nucl Med 1994;35(2):207-9.

95. Wells AU, Hansell DM, Harrison NK, Lawrence R, Black CM, du Bois RM.

Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur

Respir J 1993;6(6):797-802.

96. Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis

Clin North Am 2003;29(2):335-49, vii.

97. Yamane K. Endothelin and collagen vascular disease: a review with special

reference to Raynaud's phenomenon and systemic sclerosis. Intern Med

1994;33(10):579-82.

98. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al.

Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians

and metaanalysis of 5 studies. J Rheumatol;37(11):2290-8.

99. Ramirez A, Varga J. Pulmonary arterial hypertension in systemic sclerosis:

clinical manifestations, pathophysiology, evaluation, and management. Treat Respir Med

2004;3(6):339-52.

100. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al.

Primary pulmonary hypertension. A national prospective study. Ann Intern Med

1987;107(2):216-23.

101. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE,

et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of

pulmonary hypertension. Am J Respir Crit Care Med 2009;179(7):615-21.

102. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al.

Guidelines for the diagnosis and treatment of pulmo nary hypertension: the Task

Force for the Diagnosis and Treatment of Pulmonary Hypertension of the

European Society of Cardiology (ESC) and the Europe an Respiratory Society

(ERS), endorsed by the International Society of Hea rt and Lung Transplantation

(ISHLT). Eur Heart J 2009;30(20):2493-537.

103. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term

response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

Circulation 2005;111(23):3105-11.

EULAR Textbook on Rheumatic Diseases 104. Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, et al. Risk

factors for death and the 3-year survival of patients with systemic sclerosis: the French

ItinerAIR-Sclerodermie study. Rheumatology (Oxford) 2009;48(3):304-8.

105. Pignone A, Mori F, Pieri F, Oddo A, Galeota G, Fiori G, et al. Exercise Doppler

echocardiography identifies preclinic asymptomatic pulmonary hypertension in systemic

sclerosis. Ann N Y Acad Sci 2007;1108:291-304.

106. D'Alto M, Ghio S, D'Andrea A, Pazzano AS, Argiento P, Camporotondo R, et al.

Inappropriate exercise-induced increase in pulmonary artery pressure in patients with

systemic sclerosis. Heart;97(2):112-7.

107. Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al. The

three-year incidence of pulmonary arterial hypertension associated with systemic

sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum

2009;60(6):1831-9.

108. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al.

Hemodynamic predictors of survival in scleroderma-related pulmonary arterial

hypertension. Am J Respir Crit Care Med;182(2):252-60.

109. Avouac J, Kowal-Bielecka O, Pittrow D, Huscher D, Behrens F, Denton CP, et al.

Validation of the 6 min walk test according to the OMERACT filter: a systematic literature

review by the EPOSS-OMERACT group. Ann Rheum Dis;69(7):1360-3.

110. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical

correlates and prognostic significance of six-minute walk test in patients with primary

pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J

Respir Crit Care Med 2000;161(2 Pt 1):487-92.

111. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubenfire M.

Oxygen desaturation on the six-minute walk test and mortality in untreated primary

pulmonary hypertension. Eur Respir J 2001;17(4):647-52.

112. Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise

capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis

of randomised controlled trials. Ann Rheum Dis 2008;67(6):808-14.

113. Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, et al. Role of N-

terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary

arterial hypertension. Eur Heart J 2006;27(12):1485-94.

EULAR Textbook on Rheumatic Diseases 114. Allanore Y, Meune C. N-terminal pro brain natriuretic peptide: the new

cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol

2009;27(3 Suppl 54):59-63.

115. Steen V, Medsger TA, Jr. Predictors of isolated pulmonary hypertension in

patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum

2003;48(2):516-22.

116. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-

terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon

monoxide as independent predictors of the occurrence of precapillary pulmonary arterial

hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58(1):284-91.

117. Manetti M, Allanore Y, Revillod L, Fatini C, Guiducci S, Cuomo G, et al. A genetic

variation located in the promoter region of the UPAR (CD87) gene is associated with the

vascular complications of systemic sclerosis. Arthritis Rheum;63(1):247-56.

118. Wipff J, Dieude P, Guedj M, Ruiz B, Riemekasten G, Cracowski J, et al.

Association of KCNA5 gene polymorphism with systemic sclerosis-associated

pulmonary arterial hypertension in the European Caucasian population. Arthritis Rheum.

119. Deswal A, Follansbee WP. Cardiac involvement in scleroderma. Rheum Dis Clin

North Am 1996;22(4):841-60.

120. Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of

progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation

1976;53(3):483-90.

121. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in

systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight

matched controls. Am J Med 1969;46(3):428-40.

122. Ferri C, Emdin M, Giuggioli D, Carpeggiani C, Maielli M, Varga A, et al.

Autonomic dysfunction in systemic sclerosis: time and frequency domain 24 hour heart

rate variability analysis. Br J Rheumatol 1997;36(6):669-76.

123. Kostis JB, Seibold JR, Turkevich D, Masi AT, Grau RG, Medsger TA, Jr., et al.

Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med

1988;84(6):1007-15.

124. Follansbee WP, Zerbe TR, Medsger TA, Jr. Cardiac and skeletal muscle disease

in systemic sclerosis (scleroderma): a high risk association. Am Heart J

1993;125(1):194-203.

EULAR Textbook on Rheumatic Diseases 125. Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, et al. Cardiac

involvement in systemic sclerosis assessed by tissue-doppler echocardiography during

routine care: A controlled study of 100 consecutive patients. Arthritis Rheum

2008;58(6):1803-9.

126. Mady C, Fernandes F, Arteaga E, Ramires FJ, Buck Pde C, Salemi VM, et al.

Serum NT pro-BNP: relation to systolic and diastolic function in cardiomyopathies and

pericardiopathies. Arq Bras Cardiol 2008;91(1):46-54.

127. Ferri C, Emdin M, Nielsen H, Bruhlmann P. Assessment of heart involvement.

Clin Exp Rheumatol 2003;21(3 Suppl 29):S24-8.

128. Phan TG, Cass A, Gillin A, Trew P, Fertig N, Sturgess A. Anti-RNA polymerase

III antibodies in the diagnosis of scleroderma renal crisis sine scleroderma. J Rheumatol

1999;26(11):2489-92.

129. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 1996;22(4):861-

78.

130. Lee S, Lee S, Sharma K. The pathogenesis of fibrosis and renal disease in

scleroderma: recent insights from glomerulosclerosis. Curr Rheumatol Rep

2004;6(2):141-8.

131. Kovalchik MT, Guggenheim SJ, Silverman MH, Robertson JS, Steigerwald JC.

The kidney in progressive systemic sclerosis: a prospective study. Ann Intern Med

1978;89(6):881-7.

132. Livi R, Teghini L, Pignone A, Generini S, Matucci-Cerinic M, Cagnoni M. Renal

functional reserve is impaired in patients with systemic sclerosis without clinical signs of

kidney involvement. Ann Rheum Dis 2002;61(8):682-6.

133. Baron M, Lee P, Keystone EC. The articular manifestations of progressive

systemic sclerosis (scleroderma). Ann Rheum Dis 1982;41(2):147-52.

134. Mau W, Listing J, Huscher D, Zeidler H, Zink A. Employment across chronic

inflammatory rheumatic diseases and comparison with the general population. J

Rheumatol 2005;32(4):721-8.

135. Brower LM, Poole JL. Reliability and validity of the Duruoz Hand Index in persons

with systemic sclerosis (scleroderma). Arthritis Rheum 2004;51(5):805-9.

136. Poole JL, Gallegos M, O'Linc S. Reliability and validity of the Arthritis Hand

Function Test in adults with systemic sclerosis (scleroderma). Arthritis Care Res

2000;13(2):69-73.

EULAR Textbook on Rheumatic Diseases 137. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to

determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4(1):27-31.

138. Tuffanelli DL, Winkelmann RK. Systemic scleroderma, A clinical study of 727

cases. Arch Dermatol 1961;84:359-71.

139. Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y, et al.

Characteristics of joint involvement and relationships with systemic inflammation in

systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group

(EUSTAR) database. J Rheumatol;37(7):1488-501.

140. Cuomo G, Zappia M, Abignano G, Iudici M, Rotondo A, Valentini G.

Ultrasonographic features of the hand and wrist in systemic sclerosis.

Rheumatology (Oxford) 2009. 48(11):1414-7.

141. Low AH, Lax M, Johnson SR, Lee P. Magnetic resonance imaging of the hand in


142. Avouac J, Guerini H, Wipff J, Assous N, Chevrot A, Kahan A, et al. Radiological

hand involvement in systemic sclerosis. Ann Rheum Dis 2006;65(8):1088-92.

143. Cohen MJ, Persellin RH. Coexistence of rheumatoid arthritis and systemic

sclerosis in four patients. Scand J Rheumatol 1982;11(4):241-5.

144. Armstrong RD, Gibson T. Scleroderma and erosive polyarthritis: a disease

entity? Ann Rheum Dis 1982;41(2):141-6.

145. Baron M, Srolovitz H, Lander P, Kapusta M. The coexistence of rheumatoid

arthritis and scleroderma: a case report and review of the literature. J Rheumatol

1982;9(6):947-50.

146. Avouac J, Airò P, Dieude P, Caramaschi P, Tiev K, Diot E, et al. Associated

autoimmune diseases in Systemic Sclerosis define a subset of patients with milder

disease: results from two large cohorts of European Caucasian patients. J Rheumatol

2010;37(3):608-14

147. Blocka KL, Bassett LW, Furst DE, Clements PJ, Paulus HE. The arthropathy of

advanced progressive systemic sclerosis. A radiographic survey. Arthritis Rheum

1981;24(7):874-84.

148. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic

citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann

Rheum Dis 2006;65(7):845-51.

EULAR Textbook on Rheumatic Diseases 149. La Montagna G, Sodano A, Capurro V, Malesci D, Valentini G. The arthropathy

of systemic sclerosis: a 12 month prospective clinical and imaging study. Skeletal Radiol

2005;34(1):35-41.

150. Koutaissoff S, Vanthuyne M, Smith V, De Langhe E, Depresseux G, Westhovens

R, et al. Hand Radiological Damage in Systemic Sclerosis: Comparison with a Control

Group and Clinical and Functional Correlations. Semin Arthritis Rheum 2011;40(5):455-

60

151. Allanore Y, Seror R, Chevrot A, Kahan A, Drape JL. Hand vascular involvement

assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum

2007;56(8):2747-54.

152. La Montagna G, Baruffo A, Tirri R, Buono G, Valentini G. Foot involvement in

systemic sclerosis: a longitudinal study of 100 patients. Semin Arthritis Rheum

2002;31(4):248-55.

153. Rodnan GP, Medsger TA. The rheumatic manifestaions of progressive systemic

sclerosis (scleroderma). Clin Orthop Relat Res 1968;57:81-93.

154. Steen VD, Medsger TA, Jr. The palpable tendon friction rub: an important

physical examination finding in patients with systemic sclerosis. Arthritis Rheum

1997;40(6):1146-51.

155. Avouac J, Mogavero G, Guerini H, Drape JL, Mathieu A, Kahan A, et al.

Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective

study. Ann Rheum Dis. 2011;70(4):630-3

156. Mugino H, Ikemura K. Progressive systemic sclerosis with spontaneous fracture

due to resorption of the mandible: a case report. J Oral Maxillofac Surg

2006;64(7):1137-9.

157. Scharer L, Smith DW. Resorption of the terminal phalanges in scleroderma.

Arthritis Rheum 1969;12(1):51-63.

158. Braun-Moscovici Y, Furst DE, Markovits D, Rozin A, Clements PJ, Nahir AM, et

al. Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosis. J

Rheumatol 2008;35(11):2201-5.

159. Vacca A, Cormier C, Piras M, Mathieu A, Kahan A, Allanore Y. Vitamin D

deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis.

J Rheumatol 2009;36(9):1924-9.

EULAR Textbook on Rheumatic Diseases 160. Clements PJ, Furst DE, Campion DS, Bohan A, Harris R, Levy J, et al. Muscle

disease in progressive systemic sclerosis: diagnostic and therapeutic considerations.


161. Tuffanelli DL. Scleroderma and its relationship to the "collagenoses":

dermatomyositis, lupus erythematosus, rheumatoid arthritis and Sjogren's syndrome. Am

J Med Sci 1962;243:133-46.

162. Ranque B, Authier FJ, Le-Guern V, Pagnoux C, Berezne A, Allanore Y, et al. A

descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann

Rheum Dis 2009;68(9):1474-7.

163. Medsger TA, Jr., Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with

systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic

factors in 309 patients. Ann Intern Med 1971;75(3):369-76.

164. Altman RD, Medsger TA, Jr., Bloch DA, Michel BA. Predictors of survival in

systemic sclerosis (scleroderma). Arthritis Rheum 1991;34(4):403-13.

165. Clements PJ, Furst DE, Wong WK, Mayes M, White B, W igley F, et al. High-

dose versus low-dose D-penicillamine in early diffu se systemic sclerosis: analysis

of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum

1999;42(6):1194-203.

166. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de

Putte LB. Comparison of methotrexate with placebo in the treatment of systemic

sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational

trial. Br J Rheumatol 1996;35(4):364-72.

167. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in

systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum

1994;37(5):729-35.

168. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is

associated with pulmonary function and survival benefit in patients with scleroderma and

alveolitis. Ann Intern Med 2000;132(12):947-54.

169. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al.

Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med

2006;354(25):2655-66.

170. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A

multicenter, prospective, randomized, double-blind, placebo-controlled trial of

EULAR Textbook on Rheumatic Diseases corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the

treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54(12):3962-70.

171. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, et al. Impact of

oral cyclophosphamide on health-related quality of life in patients with active

scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum

2007;56(5):1676-84.

172. Avouac J, Kowal-Bielecka O, Landewe R, Chwiesko S, Miniati I, Czirjak L, et al.

European League Against Rheumatism (EULAR) Scleroderma Trial and Research group

(EUSTAR) recommendations for the treatment of systemic sclerosis: methods of

elaboration and results of systematic literature research. Ann Rheum Dis

2009;68(5):629-34.

173. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et

al. EULAR recommendations for the treatment of syst emic sclerosis: a report from

the EULAR Scleroderma Trials and Research group (EU STAR). Ann Rheum Dis

2009;68(5):620-8.

174. Tyndall A, Matucci-Cerinic M. Haematopoietic stem cell transplantation for the

treatment of systemic sclerosis and other autoimmune disorders. Expert Opin Biol Ther

2003;3(7):1041-9.

175. Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, et al.

Autologous bone marrow transplantation in the treatment of refractory systemic

sclerosis: early results from a French multicentre phase I-II study. Br J Haematol

2002;119(3):726-39.

176. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, et al.

Autologous stem cell transplantation in the treatment of systemic sclerosis: report from

the EBMT/EULAR Registry. Ann Rheum Dis 2004;63(8):974-81.

177. Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic

intestinal pseudo-obstruction: description of six cases with a positive response. Aliment

Pharmacol Ther 2004;19(6):687-94.

178. Marie I. [Gastrointestinal involvement in systemic sclerosis]. Presse Med

2006;35(12 Pt 2):1952-65.

179. Hachulla E. [Treatment of pulmonary arterial hypertension associated to systemic

sclerosis]. Rev Med Interne 2004;25(3):195-200.

EULAR Textbook on Rheumatic Diseases 180. Joglekar A, Tsai FS, McCloskey DA, Wilson JE, Seibold JR, Riley DJ. Bosentan

in pulmonary arterial hypertension secondary to scleroderma. J Rheumatol

2006;33(1):61-8.

181. Ahmadi-Simab K, Lamprecht P, Gross WL. Successful therapy of bosentan-

refractory pulmonary arterial hypertension (PAH) with inhalative iloprost. Clin Exp

Rheumatol 2005;23(3):402-3.

182. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al.

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor

antagonist sitaxsentan. J Am Coll Cardiol 2006;47(10):2049-56.

183. Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic,

functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist,

sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.

Chest 2004;126(4):1377-81.

184. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al.

Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol

2005;46(3):529-35.

185. Oudiz RJ, Barst RJ, Hansen JE, Sun XG, Garofano R, Wu X, et al.

Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial

hypertension. Am J Cardiol 2006;97(1):123-6.

186. Oudiz RJ, Galie N, Olschewski H, Torres F, Frost A, Ghofrani HA, et al. Long-

term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll

Cardiol 2009;54(21):1971-81.

187. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al.

Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-9.

188. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil

citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148-57.

189. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et

al. Continuous intravenous epoprostenol for pulmonary hypertension due to the

scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med

2000;132(6):425-34.

190. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous

subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary

EULAR Textbook on Rheumatic Diseases arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir

Crit Care Med 2002;165(6):800-4.

191. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical

therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical

practice guidelines. Chest 2007;131(6):1917-28.

192. Steen VD, Costantino JP, Shapiro AP, Medsger TA, Jr. Outcome of renal crisis in

systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE)

inhibitors. Ann Intern Med 1990;113(5):352-7.

193. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers

for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44(8):1841-7.

194. Pope JE. The diagnosis and treatment of Raynaud's phenomenon: a practical

approach. Drugs 2007;67(4):517-25.

195. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al.

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral

endothelin receptor antagonist. Arthritis Rheum 2004;50(12):3985-93.

196. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et

al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the

RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis;70(1):32-

8.

197. Nacci F, Righi A, Conforti ML, Miniati I, Fiori G, Martinovic D, et al. Intravenous

immunoglobulins improve the function and ameliorate joint involvement in systemic

sclerosis: a pilot study. Ann Rheum Dis 2007;66(7):977-9.

198. Allanore Y, Devos-Francois G, Caramella C, Boumier P, Jounieaux V, Kahan A.

Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient

treated with adalimumab. Ann Rheum Dis 2006;65(6):834-5.

199. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM,

Decuman S, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label

clinical and histopathological study. Ann Rheum Dis;69(1):193-7.

200. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B cell depletion

with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum

2009;60(2):578-83.

EULAR Textbook on Rheumatic Diseases 201. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian

C, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-

principle study. Rheumatology (Oxford);49(2):271-80.

EULAR Textbook on Rheumatic Diseases

References chapter 23

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma).

Subcommittee for scleroderma criteria of the American Rheumatism Association

Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23(5):581-90.

2. Poormoghim H, Lucas M, Fertig N, Medsger TA, Jr. Systemic sclerosis sine

scleroderma: demographic, clinical, and serologic features and survival in forty-eight

patients. Arthritis Rheum 2000;43(2):444-51.

3. Mayes MD, Lacey JV, Jr., Beebe-Dimmer J, Gillespie BW, Cooper B, Laing

TJ, et al. Prevalence, incidence, survival, and dis ease characteristics of systemic

sclerosis in a large US population. Arthritis Rheum 2003;48(8):2246-55.

4. Czirjak L, Kiss CG, Lovei C, Suto G, Varju C, Fuzesi Z, et al. Survey of

Raynaud's phenomenon and systemic sclerosis based on a representative study of

10,000 south-Transdanubian Hungarian inhabitants. Clin Exp Rheumatol

2005;23(6):801-8.

5. Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID. A study of the prevalence

of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004;43(5):596-602.

6. Kettaneh A, Al Moufti O, Tiev KP, Chayet C, Toledano C, Fabre B, et al.

Occupational exposure to solvents and gender-related risk of systemic sclerosis: a

metaanalysis of case-control studies. J Rheumatol 2007;34(1):97-103.

7. Bovenzi M, Barbone F, Pisa FE, Betta A, Romeo L, Tonello A, et al. A case-

control study of occupational exposures and systemic sclerosis. Int Arch Occup Environ

Health 2004;77(1):10-6.

8. Mayes MD. Epidemiologic studies of environmental agents and systemic

autoimmune diseases. Environ Health Perspect 1999;107 Suppl 5:743-8.

9. Diot E, Lesire V, Guilmot JL, Metzger MD, Pilore R, Rogier S, et al. Systemic

sclerosis and occupational risk factors: a case-control study. Occup Environ Med

2002;59(8):545-9.

10. Garabrant DH, Lacey JV, Jr., Laing TJ, Gillespie BW, Mayes MD, Cooper BC, et

al. Scleroderma and solvent exposure among women. Am J Epidemiol 2003;157(6):493-

500.

EULAR Textbook on Rheumatic Diseases 11. Jimenez SA, Artlett CM. Microchimerism and systemic sclerosis. Curr Opin

Rheumatol 2005;17(1):86-90.

12. Hamamdzic D, Kasman LM, LeRoy EC. The role of infectious agents in the

pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2002;14(6):694-8.

13. Herrick AL, Matucci Cerinic M. The emerging problem of oxidative stress and the

role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001;19(1):4-8.

14. Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr

Rheumatol Rep 2002;4(2):99-107.

15. Allanore Y, Dieude P, Boileau C. Updating the genetics of systemic sclerosis.

Curr Opin Rheumatol.

16. Jungel A, Ospelt C, Gay S. What can we learn from epigenetics in the year

2009? Curr Opin Rheumatol;22(3):284-92.

17. Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis.

Autoimmun Rev 2003;2(4):181-91.

18. Neidhart M, Kuchen S, Distler O, Bruhlmann P, Michel BA, Gay RE, et al.

Increased serum levels of antibodies against human cytomegalovirus and prevalence of

autoantibodies in systemic sclerosis. Arthritis Rheum 1999;42(2):389-92.

19. Jimenez SA, Diaz A, Khalili K. Retroviruses and the pathogenesis of systemic

sclerosis. Int Rev Immunol 1995;12(2-4):159-75.

20. Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin

lesions from women with systemic sclerosis. N Engl J Med 1998;338(17):1186-91.

21. Artlett CM. Microchimerism and scleroderma: an update. Curr Rheumatol Rep

2003;5(2):154-9.

22. Nelson JL. Microchimerism and HLA relationships of pregnancy: implications for

autoimmune diseases. Curr Rheumatol Rep 2001;3(3):222-9.

23. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am

1996;22(4):675-94.

24. Renaudineau Y, Revelen R, Levy Y, Salojin K, Gilburg B, Shoenfeld Y, et al.

Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol

1999;6(2):156-60.

25. Kahaleh B. Lymphocyte interactions with the vascular endothelium in systemic

sclerosis. Clin Dermatol 1994;12(3):361-7.

EULAR Textbook on Rheumatic Diseases 26. Kahaleh MB. Vascular involvement in systemic sclerosis (SSc). Clin Exp

Rheumatol 2004;22(3 Suppl 33):S19-23.

27. Gruschwitz MS, Hornstein OP, von Den Driesch P. Correlation of soluble

adhesion molecules in the peripheral blood of scleroderma patients with their in situ

expression and with disease activity. Arthritis Rheum 1995;38(2):184-9.

28. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules

(sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in

patients with systemic sclerosis: relationship to organ systemic involvement. Clin

Rheumatol 2005;24(2):111-6.

29. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy

assessment of microvascular damage in systemic sclerosis. J Rheumatol

2000;27(1):155-60.

30. Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A. Levels of

circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol

2007;25(1):60-6.

31. Avouac J, Juin F, Wipff J, Couraud PO, Chiocchia G, Kahan A, et al. Circulating

endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann

Rheum Dis 2008;67(10):1455-60.

32. Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C, et al. Bone

marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum

2006;54(8):2605-15.

33. Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, et al. Impairment

of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells:

new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum

2007;56(6):1994-2004.

34. Butler AR, Flitney FW, Williams DL. NO, nitrosonium ions, nitroxide ions,

nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol Sci

1995;16(1):18-22.

35. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI.

Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and


36. Avouac J, Borderie D, Ekindjian OG, Kahan A, Allanore Y. High DNA oxidative

damage in systemic sclerosis. J Rheumatol;37(12):2540-7.